Literature DB >> 8290428

New markers of bone and collagen turnover in children and adults with growth hormone deficiency.

A Sartorio1, A Conti, M Monzani.   

Abstract

Serum bone Gla protein (BGP), a marker of osteoblastic function, serum carboxyterminal cross-linked telopeptide of type I collagen (ICTP), a marker of bone resorption, and serum aminoterminal propeptide of type III procollagen (PIIINP) levels, an index of collagen synthesis, were determined in seven children and eight adults with congenital growth hormone deficiency (GHD). In children with GHD, serum BGP (mean +/- s.e.: 12.9 +/- 0.7 ng/ml), ICTP (8.3 +/- 1.3 ng/ml) and PIINP (3.5 +/- 0.5 ng/ml) levels were significantly lower (P < 0.001) than those recorded in normal children (BGP 18.9 +/- 0.8 ng/ml, ICTP 14.4 +/- 0.5 ng/ml and PIIINP 6.7 +/- 0.7 ng/ml). Total alkaline phosphatase (184.7 +/- 13.4 IU/l) and bone alkaline phosphatase (77.8 +/- 4.1 IU/l) levels were also significantly lower (P < 0.0001) than in controls (338.1 +/- 14.9 IU/l and 181.0 +/- 7.8 IU/l, respectively). Serum BGP, ICTP and PIIINP levels were not significantly correlated with height velocity values. In adults with GHD, mean BGP levels (3.8 +/- 0.3 ng/ml) were significantly lower (P < 0.0001) than those recorded in normals (5.4 +/- 0.1 ng/ml). On the contrary, serum ICTP levels were similar to those found in controls (patients: 4.7 +/- 0.8 ng/ml vs normals: 4.1 +/- 0.3 ng/ml), suggesting the presence of a normal resorption activity associated with a reduced osteoblastic function. This finding was also confirmed by the presence of reduced bone alkaline phosphatase levels (GHD: 44.9 +/- 6.9 IU/I vs controls: 58.3 +/- 2.0 IU/I; P<0.02), while the less specific total alkaline phosphatase levels (119.5 +/- 14.8 IU/I) were similar to those recorded in normal subjects (122.3 +/- 4.0 IU/I). Serum PIIINP levels (3.7 +/- 0.6 ng/ml) were similar to those recorded in normals (3.2 +/- 0.2 ng/ml), suggesting that in adulthood the collagen turnover is not negatively influenced by the chronic GHD. No significant correlations were found between BGP/ICTP/PIIINP and IGF-I levels. In conclusion, our data show that in children with GHD the lack of GH insulin-like growth factor-I (IGF-I) effects on bone and collagen turnover is associated with a significant reduction of bone turnover (low bone formation plus low bone resoRption) and collagen synthesis. On the contrary, adult GHD seems to exert less relevant effects on bone and collagen turnover, probably due to the fact that in adult life further hormones or local factors might partially counteract the negative consequences of chronic GH-IGF-I deficiency.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8290428      PMCID: PMC2399931          DOI: 10.1136/pgmj.69.817.846

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  21 in total

1.  Serum osteocalcin levels in patients with GH deficiency before and during GH treatment.

Authors:  A Sartorio; A Conti; G Guzzaloni; G Faglia
Journal:  Acta Paediatr Scand       Date:  1991-01

Review 2.  Growth hormone and adult bone remodelling.

Authors:  A M Parfitt
Journal:  Clin Endocrinol (Oxf)       Date:  1991-12       Impact factor: 3.478

3.  Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset.

Authors:  J M Kaufman; P Taelman; A Vermeulen; M Vandeweghe
Journal:  J Clin Endocrinol Metab       Date:  1992-01       Impact factor: 5.958

4.  Skin collagen and thickness in acromegaly and hypopituitarism.

Authors:  M M Black; S Shuster; E Bottoms
Journal:  Clin Endocrinol (Oxf)       Date:  1972-07       Impact factor: 3.478

5.  Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma.

Authors:  S B Rosalki; A Y Foo
Journal:  Clin Chem       Date:  1984-07       Impact factor: 8.327

6.  Bone mineral status in growth hormone deficiency.

Authors:  R M Shore; R W Chesney; R B Mazess; P G Rose; G J Bargman
Journal:  J Pediatr       Date:  1980-03       Impact factor: 4.406

7.  Isolated growth hormone deficiency in prepubertal children. Influence of human growth hormone on longitudinal growth, adipose tissue, bone mass and bone maturation.

Authors:  A Ferrandez; M Zachmann; A Prader; R Illig
Journal:  Helv Paediatr Acta       Date:  1970-12

8.  New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease.

Authors:  P A Price; J G Parthemore; L J Deftos
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

9.  Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy.

Authors:  J S Johansen; S B Jensen; B J Riis; L Rasmussen; M Zachmann; C Christiansen
Journal:  J Clin Endocrinol Metab       Date:  1990-07       Impact factor: 5.958

Review 10.  [Biological markers of bone metabolism].

Authors:  P D Delmas
Journal:  Presse Med       Date:  1993-02-20       Impact factor: 1.228

View more
  10 in total

1.  Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.

Authors:  A Sartorio; N Marazzi; F Agosti; G Faglia; C Corradini; E De Palo; S Cella; A Rigamonti; E E Muller
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

2.  Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency.

Authors:  A Sartorio; S Ortolani; A Conti; R Cherubini; E Galbiati; G Faglia
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

3.  Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.

Authors:  A Conti; A Sartorio; S Ferrero; S Ferrario; B Ambrosi
Journal:  J Endocrinol Invest       Date:  1996-02       Impact factor: 4.256

4.  Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.

Authors:  A Sartorio; G Conte; A Conti; A Masala; S Alagna; P Rovasio; G Faglia
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

5.  Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.

Authors:  A Sartorio; M Arosio; A Conti; S Ferrero; S Porretti; G Faglia
Journal:  J Endocrinol Invest       Date:  1999-03       Impact factor: 4.256

6.  Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover.

Authors:  A Sartorio; A Conti; M Monzani; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

7.  Peripheral bone mineral density in correlation to disease-related predisposing conditions in patients with multiple endocrine neoplasia type 1.

Authors:  P H Kann; D Bartsch; P Langer; J Waldmann; P Hadji; A Pfützner; J Klüsener
Journal:  J Endocrinol Invest       Date:  2011-07-27       Impact factor: 4.256

8.  Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency.

Authors:  A Sartorio; S Ortolani; E Galbiati; G Conte; V Vangeli; M Arosio; S Porretti; G Faglia
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

Review 9.  [Growth hormone therapy in adult patients: a review].

Authors:  Peter Herbert Kann
Journal:  Wien Klin Wochenschr       Date:  2011-05-18       Impact factor: 1.704

10.  Serum bone Gla protein and carboxyterminal cross-linked telopeptide of type I collagen in patients with Cushing's syndrome.

Authors:  A Sartorio; A Conti; S Ferrario; E Passini; T Re; B Ambrosi
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.